HC Wainwright Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX)
HC Wainwright reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $8.00 target price on the stock. A number of other research firms also recently issued reports on GANX. Chardan Capital reaffirmed a “buy” rating and […]
HC Wainwright reaffirmed their buy rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $8.00 target price on the stock. A number of other research firms also recently issued reports on GANX. Chardan Capital reaffirmed a “buy” rating and […]
